Letter from the Editor

Dear Colleagues,

It is my privilege to introduce this report on the 31^st United European Gastroenterology Week (UEGW), held from 12 to 15 October 2024 in the captivating city of Vienna, Austria. This year’s congress showcased a wealth of cutting-edge research, innovative therapeutics, and meaningful discussions across the spectrum of gastroenterology.

Within these pages, you will find detailed insights into key topics from the event, ranging from advances in inflammatory bowel disease (IBD) treatments and prevention strategies to breakthroughs in pancreatic diagnostics, irritable bowel syndrome management, and liver therapeutics. Highlights include promising results for novel agents such as mirikizumab and etrasimod in IBD, improved algorithms for pancreatic care, and novel approaches in faecal microbiota transplantation.

As a member of the organising committee, I am especially proud of the exceptional collaboration and dedication that went into curating this impactful event. I would like to thank my fellow committee members, the speakers, and all contributors for their invaluable efforts in making this congress a success. Whether you were among the participants in Vienna or are joining us through this report, I hope these summaries offer valuable perspectives to enhance your practice and inspire innovation in your work.

Warm regards,

Dr Marjolijn Duijvestein

Biography

Marjolijn Duijvestein works as a gastroenterologist in the IBD team of the Radboudumc in Nijmegen, the Netherlands. In 2012, she obtained her PhD at Leiden University and was trained as a gastroenterologist specialised in IBD disease at the Amsterdam UMC in Amsterdam. As part of her training, she gained experience at the University of California San Diego (UCSD, USA) and performed an internship at Alimentiv (former Robarts Clinical Trials), an academic research organisation dedicated to drug development for IBD. Her clinical activity and research are focused on IBD, in particular clinical and translational research.

Conflict of Interest Statement:
Has served as an advisor for Echo Pharma and Robarts Clinical Trials, reports nonfinancial support from Dr Falk Pharma, and received speaker fees from Janssen, Merck & Co., Pfizer, Takeda and Tillotts Pharma. Advisory boards Janssen, Takeda, BMS and Abbvie.



Posted on 28 November 202428 November 2024